We evaluated KIM-1 and circulating tumor DNA in a prospective cohort of patients treated with radiation therapy alone for oligometastatic clear cell renal cell carcinoma. This is the first evaluation of both KIM-1 and ctDNA in the same cohort, and we found that both were prognostic for the primary endpoint of systemic therapy-free survival. We further integrated both of these markers, ctDNA and KIM-1, with four clinical variables to develop the K-Compass model, which had excellent discrimination and calibration to evaluate patients and identify patients who do very well with a treatment strategy of radiation without systemic therapy...
We evaluated KIM-1 and circulating tumor DNA in a prospective cohort of patients treated with radiation therapy alone for oligometastatic clear cell renal cell carcinoma. This is the first evaluation of both KIM-1 and ctDNA in the same cohort, and we found that both were prognostic for the primary endpoint of systemic therapy-free survival. We further integrated both of these markers, ctDNA and KIM-1, with four clinical variables to develop the K-Compass model, which had excellent discrimination and calibration to evaluate patients and identify patients who do very well with a treatment strategy of radiation without systemic therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
